

## **REMARKS**

### **Status of the Claims**

Claims 24, 28, and 30-51 are currently pending in the present application. Claims 1-23, 25-27 and 29 have been canceled without prejudice or disclaimer of the subject matter claimed therein.

Claims 28 and 36 are withdrawn from consideration as being directed to a non-elected species. Thus, claims 24, 30-35, and 37-51 are currently being examined.

### **Amendments to the Claims**

Claims 24, 28, 30, 35-41, and 43-49 have been amended and new claims 50 and 51 have been added to more clearly define the claimed invention. The amendment to these claims and the addition of new claims do not include prohibited new matter.

Claims 24, 28, 30, 35-41, and 43-49 have been amended to insert “antibody.” Support for the insertion of “antibody” into the claim can be found on page 17, line 13.

Claims 24 and 46 have been amended to replace “binds to” with “opsonizes.” Support for this amendment can be found in original claim 29.

Claims 24 and 46 have also been amended to insert “induces removal of amyloid deposit.” Support for this amendment can be found on page 16, line 16 and Example 2.

Support for new claim 50 can be found on page 18, lines 19-21.

Support for new claim 51 can be found in original claim 24 and on page 18, lines 28 and 29.

### **Rejections Under 35 U.S.C. § 102**

A. Claims 24, 29-31, 35, 39-46, 48, and 49 are rejected under 35 U.S.C. 102(b) as being anticipated by Konig *et al.* (WO 96/25435).

The claims as they stand are generally directed to methods of removing amyloid deposits from a patient comprising administering an effective amount of an antibody or immunoglobulin polypeptide or fragment thereof to the patient, wherein the antibody or immunoglobulin polypeptide or fragment thereof opsonizes an amyloid fibril and induces removal of amyloid deposits. Example 2 shows antibody or immunoglobulin inducing the removal of amyloid

deposits. New claim 50 includes the limitation that the antibody or immunoglobulin polypeptide or fragment thereof opsonizes an epitope shared by amyloid fibrils. New claim 51 includes the limitation that the antibody or immunoglobulin polypeptide or fragment thereof cross-reacts with amyloid fibrils comprising precursor proteins different from the precursor proteins in an antigen used to generate the antibody or immunoglobulin.

Applicants respectfully submit that the disclosure of Konig *et al.* is not the same as the instant invention and therefore does not anticipate the pending claims. Konig *et al.* merely teach *in vitro* methods of labeling amyloid plaques present in the brain of a human patient, using immunohistochemical techniques involving monoclonal antibodies that bind beta-A4 peptide. The Office asserts that Konig *et al.* generally discuss diagnostic and therapeutic uses of such antibodies in the diagnosis and treatment of Alzheimers diseases. Konig *et al.*, however, do not teach administration of antibodies to a patient for the removal of amyloid deposits as is claimed. In fact, Konig *et al.* do not even contemplate the use of the monoclonal antibody to remove amyloid fibrils from a patient as is claimed. Accordingly, on this issue alone, Konig *et al.* do not anticipate the claimed invention.

Applicants respectfully submit that the pending claims require administering an antibody or immunoglobulin polypeptide or fragment thereof in an amount effective to remove amyloid deposits in a patient. Konig *et al.* do not disclose administering an effective amount of an antibody or immunoglobulin polypeptide to remove amyloid deposits from a patient. Contrary to the assertions of the Examiner, claims 9-19 of Konig *et al.* are directed to methods of using the antibody to detect the presence of  $\beta$ A4 peptide, to selectively purify  $\beta$ A4 peptide from a tissue sample, and to prevent aggregation of  $\beta$ A4 peptide. (Claim 20 is directed to a method of generating an antibody using a peptide.) The method claims of Konig *et al.* include the limitation that the method be performed with a tissue sample. Thus, Konig *et al.* do not contemplate administering an antibody in an effective amount to remove amyloid deposits in a patient.

Moreover, the claimed invention requires that the antibody or immunoglobulin polypeptide or fragment thereof opsonizes an amyloid fibril and induces removal of amyloid deposits. Konig *et al.* do not disclose an antibody that opsonizes an amyloid fibril and induces removal of amyloid deposits.

Applicants also respectfully submit that Konig *et al.* provide nothing more than a general unsupported statement that the disclosed monoclonal antibodies could be used for the treatment of AD. As has already been demonstrated by Applicants in the declaration of Dr. Biere submitted on October 23, 2002, the mere binding of an antibody to amyloid fibril for diagnostic purposes is not sufficiently predictive of its ability to remove amyloid fibril from a patient. The reference of Konig *et al.* fails to provide a disclosure that enables the claimed methods. For instance, Konig *et al.* do not show that their monoclonal antibodies are effective for the removal of amyloid deposits as required by the claims. Accordingly, the teachings of Konig *et al.* do not enable one of skill in the art to make and use the claimed invention, and Konig *et al.* is not a reference under 35 U.S.C. § 102(b). The Federal Circuit has held that to anticipate, a reference must also enable one of skill in the art to make and use the claimed invention. See *Minnesota Manufacturing and Mining v. Chemque, Inc.*, 303 F.3d 1294 (Fed. Cir. 2002); *Elan Pharmaceuticals v. Mayo Foundation*, 68 USPQ2d 1373, 1375 (Fed. Cir. 2003).

Unlike the antibodies of Konig *et al.*, which are generated using the  $\beta$ A4(35-42) peptide, the antibodies of the present invention are generated using amyloid fibrils. As shown in Examples 3 and 4, the antibodies of the present invention exhibit cross-isotype reactivity because they bind amyloids in a non-subgroup specific manner. Moreover, Example 7 shows that the antibodies of the present invention, which are generated using  $\lambda$ 6 light chain amyloid fibrils, cross-react with murine AA amyloids and synthetic fibrils composed of  $\beta$ A4(25-35). The antibodies of the present invention bind amyloids comprising precursor proteins different from the precursor proteins in the antigen used to generate the antibodies. They recognize an epitope that is shared among amyloid fibrils.

The work of O'Nuallain *et al.* confirms the results of the present application that amyloid fibrils have a conformational epitope that is shared among amyloid fibrils but is absent from their native precursor proteins and that antibodies generated using amyloid fibrils recognize this conformational epitope. As shown by O'Nuallain *et al.*, the WO1 and WO2 antibodies, generated using amyloid fibrils, bind to the amyloid fibril state of A $\beta$ (1-40), but not to the soluble, monomeric state (O'Nuallain *et al.*, PNAS 2002, 99(3): 1485; see attached). Moreover, the WO1 and WO2 antibodies bind to other disease related fibrils such as transthyretin, islet

amyloid polypeptide,  $\beta_2$ -microglobulin, and polyglutamine, but do not bind to the native protein precursors of these amyloids.

On page 6 of the Office Action, the Examiner seems to indicate that the methods of Konig *et al.* inherently anticipate the claimed methods and that Konig *et al.* need not teach the “mechanism of action.” Applicants respectfully submit that the Examiner’s reliance on inherency is misplaced. As provided in the MPEP, the fact that a certain result may occur or be present in the prior art is not sufficient to establish the inherency of that result or characteristic. See MPEP § 2112, IV (page 2100-54) citing *In re Rijckaert*, 9 F.3d 1531, 1534, 28 USPQ2d 1955, 1957 (Fed. Cir. 1993). In relying on inherency, the Examiner must provide a basis in fact or technical reasoning to reasonably support her determination in that an inherent characteristic necessarily flows from the teachings of a prior art reference. See MPEP 2112, IV (page 2100-55) citing *Ex parte Levy*, 17 USPQ2d 1461, 1464 (Bd. Pat. App. & Inter. 1990) (emphasis in original). Respectfully, the Examiner has provided no such basis for her assertions of the inherent properties of Konig *et al.* Rather, the Examiner has made unsupported assertions of the inherent properties of the antibodies of Konig *et al.* when Applicants claims are methods. As such, it is patently unfair for the Examiner to attempt to shift the burden to Applicants to provide evidence of an “obviousness difference” between the claimed invention and the disclosure of Konig *et al.* who never administered an antibody to a patient (see page 8, line 11 of the Office Action).

Applicants also respectfully submit that any discussion of inherency as it relates to Konig *et al.* is merely academic at this point. As Applicants have previously pointed out, a reference must enable one of skill in the art to make and use the claimed invention. See *Minnesota Manufacturing and Mining v. Chemque, Inc.*, 303 F.3d 1294 (Fed. Cir. 2002); *Elan Pharmaceuticals v. Mayo Foundation*, 68 USPQ2d 1373, 1375 (Fed. Cir. 2003). On page 8, line 15, the Examiner asserts that there is “no precedent in the cited law to conclude that Konig is non-enabled. . . . The above appears to be a question of fact to which Applicants have shown no evidence or scientific reasoning that would disprove the Konig teachings.” Applicants respectfully submit that such reasoning was provided in the amendment filed March 30, 2004 in the discussion of the “Wands Factors” (page 6 of the Amendment). These arguments have been

ignored by the Examiner and the Examiner's finding that *Konig et al.* is enabling for a "method of treatment" is contradictory to the U.S. Patent Office's own examination guidelines.

The Examiner is respectfully directed to the Revised Interim Utility Guidelines Training Materials issued by the U.S. Patent Office. Although these materials are directed to examination procedures under 35 U.S.C. § 101, the materials specifically address enablement issues under 35 U.S.C. § 112, first paragraph and it is to these sections that Applicants direct the Examiner. For instance, pages 18 and 19 of the Guidelines discuss the examination of methods of "retarding the aging process" and teach that the failure to provide working examples to "provide credibility" to these claims "should result in a rejection under 35 U.S.C. § 112, first paragraph, *i.e.*, an enablement rejection. Applicants merely request that such examination standards under 35 U.S.C. § 112, first paragraph be properly applied to the teachings of *Konig et al.*

Lastly, Applicants respectfully submit that the Examiner's reliance on the combined teachings of *Konig et al.* and *Becker et al.* on page 9 of the Office Action is misplaced. In this paragraph, the Examiner appears to assert that the combined teachings indicate that the *Konig et al.* antibodies are raised against amyloid fibrils (page 9, lines 10-13). Respectfully, the Examiner cannot rely on the teachings of a secondary reference (*Becker et al.*) to contradict the supposedly anticipatory disclosure of *Konig et al.* As taught by *Konig et al.*, the disclosed antibodies are produced via immunization with peptide #959, conjugated to KLH. See Example 4, page 19. No attempts were made to polymerize this peptide into fibrils. See Example 3. Accordingly, the teachings of *Konig et al.* directly contradict the Examiner's assertions that the peptide of *Konig et al.* is in fibril form. Applicants respectfully request that the Examiner specifically acknowledge her misinterpretation of the teachings of *Konig et al.*

In summary, given the differences between the claimed invention and that disclosed by *Konig et al.*, *Konig et al.* do not anticipate the claimed invention. Applicants respectfully request withdrawal of the rejection.

B. Claims 24, 29-35, and 37-49 are rejected under 35 U.S.C. 102(b) as being anticipated by *Becker et al.* (EP 613007, David "Nettleship" Brems *et al.*).

Applicants note that "Nettleship" is the middle name of the second named inventor (David Nettleship Brems) of EP613007. "Gerald Wayne Becker" is the first named inventor of

EP 613007. Accordingly “Becker *et al.*” and “Nettleship *et al.*” (cited in the Office Action for EP 613007) refer to the same reference.

As discussed above, the claims as they stand are directed to a method of removing amyloid deposits from a patient comprising administering an antibody or immunoglobulin polypeptide or fragment thereof to the patient, wherein the antibody or immunoglobulin polypeptide or fragment thereof opsonizes an amyloid fibril and induces removal of amyloid deposits. Moreover, claims 24 and 46 have been amended to delete a component or precursor thereof.

Applicants respectfully submit that the claimed methods are different from the methods disclosed by Becker *et al.*; thus, Becker *et al.* do not anticipate the claimed invention. Becker *et al.* generally discuss parenteral administration of antibodies having a specificity for  $\beta$ -amyloid peptide in the  $\beta$ -sheet conformation. Similar to Konig *et al.*, Becker *et al.* do not provide specific guidance or examples for administering such antibodies to remove amyloid deposits from patients. Accordingly, on this issue alone, Becker *et al.* do not anticipate the claimed invention.

As discussed in the declaration of Dr. Biere which was previously submitted, the mere binding of an antibody to amyloid fibrils for diagnostic purposes does not suggest that the antibody is able to remove amyloid fibrils from a patient. Becker *et al.* have not shown that their antibodies having specificity to  $\beta$ -amyloid peptide are capable of removing amyloid deposits from a patient. A review of the claims of Becker *et al.* indicates that the contemplated inventions are methods of assaying for agents that inhibit the neurotoxicity of  $\beta$ -amyloid peptide and conformationally-specific antibodies. The method steps of Becker *et al.* do not require administering the antibodies of Becker *et al.* to a patient. Becker *et al.* have not even shown that their antibodies bind amyloid fibrils. Accordingly, Becker *et al.* neither contemplate nor enable administering the claimed antibodies to a patient to remove amyloid deposits from the patient.

Respectfully, even if Becker *et al.* generally disclose pharmaceutical compositions comprising their antibodies for parenteral administration, Becker *et al.* have not provided guidance for a method of administering antibodies for removing amyloid fibrils from a patient. Since Becker *et al.* do not enable the anticipated invention, Becker *et al.* cannot anticipate the claims.

Applicants also respectfully request that the Examiner addresses Applicants' arguments above (in the discussion on *Konig et al.*) concerning the inherency and enablement in relations to *Becker et al.* as these issues are identical to those present in *Konig et al.*

Applicants respectfully request withdrawal of the rejection.

Rejection Under 35 U.S.C. § 103(a)

Claims 24, 29-35, and 37-49 are rejected under 35 U.S.C. § 103(a) as being unpatentable over *Konig et al.* (WO 96/25435), *Becker et al.* (EP 613007, David "Nettleship" Brems *et al.*), and *Benjamini et al.* Ed. (Immunology: A Short Course).

As discussed above, the claims as they stand are directed to a method of removing amyloid deposits from a patient comprising administering an antibody or immunoglobulin polypeptide or fragment thereof to the patient, wherein the antibody or immunoglobulin polypeptide or fragment thereof opsonizes an amyloid fibril and induces removal of amyloid deposits.

The Office Action asserts that the *Konig et al.* and *Becker et al.* teach administration of  $\beta$ -amyloid antibodies for therapeutic use in Alzheimers treatment. The deficiencies of *Konig et al.* and *Becker et al.* are discussed above. Although *Konig et al.* and *Becker et al.* disclose antibodies that bind to beta-amyloid peptides, these references do not disclose a method of removing amyloid deposit from a patient comprising administering an antibody or immunoglobulin polypeptide or fragment thereof in an amount effective to opsonize an amyloid fibril and induce removal of the amyloid deposits. Accordingly, neither *Konig et al.* nor *Becker et al.* contemplate the claimed invention.

*Benjamini et al.* do not cure the deficiencies of *Konig et al.* and *Becker et al.* *Benjamini et al.* generally discuss opsonization of antigens by antibodies making them more attractive to phagocytic cells. *Benjamini et al.* do not disclose antibodies that opsonize amyloid fibrils or characterize such antibodies nor do *Benjamini et al.* induce removal of amyloid deposits using opsonizing antibodies. Accordingly, *Benjamini et al.* add nothing to the combined teachings of *Konig et al.* and/or *Becker et al.*, and there is no motivation to combine the references of *Konig et al.*, *Becker et al.* and *Benjamini et al.*

As discussed in Dr. Biere's declaration, the removal of amyloid deposits from a patient by administering antibodies to the patient is an unexpected discovery. At the time of the invention, antibodies have been successfully used as diagnostic tools in detecting the presence of amyloid deposits, but the use of antibodies to remove amyloid deposits from a patient was not known. None of these three cited references teach that antibodies could be used to remove amyloid deposits. Accordingly, the cited references do not render the claimed invention obvious and Applicants respectfully request withdrawal of the rejection.

However, neither Konig *et al.* nor Becker *et al.* teach a method of removing amyloid deposits


### **CONCLUSION**

In view of the accompanying remarks, Applicants respectfully request reconsideration and timely allowance of the pending claims. Should the Examiner feel that there are any issues outstanding after consideration of this response, the Examiner is invited to contact Applicants' undersigned representative to expedite prosecution.

If there is any fee due in connection with the filing of this Amendment, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

**MORGAN, LEWIS & BOCKIUS LLP**

  
Sally P. Teng  
Reg. No. 45,397

Dated: March 16, 2005

**Customer No. 09629**  
**MORGAN, LEWIS & BOCKIUS LLP**  
1111 Pennsylvania Ave., N.W.  
Washington, D.C. 20004  
(202) 739-3000



# Conformational Abs recognizing a generic amyloid fibril epitope

Brian O'Nuallain and Ronald Wetzel\*

Graduate School of Medicine, University of Tennessee Medical Center, 1924 Alcoa Highway, Knoxville, TN 37920

Communicated by David R. Davies, National Institutes of Health, Bethesda, MD, December 11, 2001 (received for review September 19, 2001)

Disease-related amyloid fibrils appear to share a common, but poorly understood, structure. We describe here the generation and preliminary characterization of two conformation-specific mAbs, WO1 and WO2, that bind to the amyloid fibril state of the Alzheimer's peptide A $\beta$ (1–40) but not to its soluble, monomeric state. Surprisingly, these Abs also bind to other disease-related amyloid fibrils and amyloid-like aggregates derived from other proteins of unrelated sequence, such as transthyretin, islet amyloid polypeptide,  $\beta_2$ -microglobulin, and polyglutamine. At the same time, WO1 and WO2 do not bind to the native protein precursors of these amyloids, nor do they bind to other kinds of protein aggregates. This new class of Abs associated with a fundamental amyloid-folding motif appear to recognize a common conformational epitope with little apparent dependence on amino acid side chain information. These Abs should contribute to the understanding of amyloid structure, assembly, and toxicity and also may benefit the development of diagnostic and therapeutic agents for amyloid diseases.

Amyloid fibrils are highly insoluble, ordered protein aggregates involved in a number of human diseases (1, 2), including Alzheimer's disease (3) and type II diabetes (4). Although the protein components of amyloid fibrils from various disease states differ considerably from each other in primary sequence, all amyloid fibrils share common features, including a high degree of  $\beta$ -sheet in a classical "cross- $\beta$ " pattern, a fibrillar morphology in electron microscopy, and the ability to bind and alter the spectroscopic properties of heteroaromatic dyes Congo red and thioflavin T (ThT) (5, 6). Although these common properties suggest that amyloid fibrils must share deeper similarities at the molecular level, the extent of similarity between the polypeptide-folding patterns of different amyloids is unknown. Details of the nature of the amyloid fold remain obscure because of technical limitations to obtaining high resolution structural information on large, insoluble, heterodisperse aggregates.

Although mAbs have previously proved useful in the structural analysis of globular proteins, their use in the characterization of amyloid fibril structure has been limited. Most of the anti-fibril Abs generated in an immune response to fibrils tend to be directed at unstructured portions of the amyloidogenic peptide not involved in fibril structure. In a recent characterization of the Ab response in mice injected with amyloid  $\beta$  protein (A $\beta$ ) fibrils, it was found that the majority of the Abs are directed at the N-terminal 12 residues of the peptide and are capable of crossreacting strongly with the monomeric peptide (7). This agrees well with the results of limited proteolysis studies of A $\beta$  fibrils indicating an exposed, unstructured N-terminal region in the aggregate (8). Thus, such Abs tell us about those parts of the amyloidogenic peptide that are not involved in fibril structure but little about the nature of fibril structure itself.

Identification of conformational epitopes in fibrils would therefore add an important new dimension to the structural information on fibrils available through Ab studies. Early experiments with rabbit polyclonal sera suggested that amyloid fibrils possess a nonnative structure and that Abs can be generated that are specific for the amyloidogenic conformation (9). More recently, conformational Abs have been reported that are

specific for transthyretin (TTR) amyloid fibrils (10) or for the infectious form of mammalian prions (11).

In addition to the value of anti-fibril Abs as structural probes, the nature of the immune response to amyloid is of special interest because of recent reports of successful active and passive vaccine approaches to slowing and/or reversing amyloid plaque growth and/or its pathological consequences in mouse models of light chain amyloidosis (13,  $\dagger$ ), Alzheimer's disease (14, 15), and mammalian prion disease (16). Some Abs recognizing A $\beta$  fibrils also appear capable of stimulating fibril disassembly (17) and/or preventing fibril assembly (18) *in vitro*.

We report here the results of hydridoma experiments specifically focused on generating conformation-specific Abs against A $\beta$  fibrils (19). The results suggest the existence of a major conformational epitope present in many amyloid fibrils composed of diverse protein sequences.

## Materials and Methods

**Materials and General Methods.** A $\beta$ (1–40) peptides, as well as the polyglutamine (polyGln) molecule NH<sub>2</sub>-KKQ<sub>42</sub>KK-COOH, were custom synthesized at the Keck Biotechnology Center, Yale University. Chemically synthesized, full-length human islet amyloid polypeptide (IAPP) was a gift from Per Westermark. Recombinant JTO5, an amyloidogenic Ig V<sub>L</sub> domain, was a gift of Jonathan Wall. Human  $\beta_2$ -microglobulin ( $\beta_2$ m), human TTR, and chicken lysozyme were purchased from Sigma, as were bovine collagen and acid-soluble calf collagen. The  $\kappa$  light chain IgM mAb was purchased from Calbiochem (catalog no. 401925), and an IgG mAb recognizing the 1–17 sequence of A $\beta$ , MAB1560, was purchased from Chemicon. Gelatin was from Bio-Rad. Trifluoroacetic acid was from Pierce and 1,1,1,3,3,3-hexafluoro-2-isopropyl alcohol (HFIP) from Sigma.

Unless otherwise indicated, all quantitative experimental results shown are from measurements done in triplicate. Error bars in figures represent SDs.

**Preparation of Solubilized Peptides and Amyloid Fibrils.** Each peptide and protein required customized protocols for fibril formation. With the exception of polyGln aggregates, all amyloid fibrils, as well as collagen and elastin, were sonicated on ice with a probe sonicator for five consecutive 30-sec pulses before immobilization onto plastic microtiter plates.

A $\beta$  peptides were solubilized and aggregated by a variation of the previously described protocol (8, 20). Amyloid fibrils were grown from A $\beta$ (1–40) by incubating a 0.25 mg/ml disaggregated solution of the peptide in PBS containing 0.05% sodium azide (PBSA) at 37°C together with a seed consisting of 0.1% by weight

Abbreviations: PBSA, PBS containing 0.05% sodium azide; polyGln, polyglutamine; IAPP, islet amyloid polypeptide; A $\beta$ , amyloid  $\beta$  protein; TTR, transthyretin;  $\beta_2$ m,  $\beta_2$ -microglobulin; ThT, thioflavin T.

\*To whom reprint requests should be addressed. E-mail: r.wetzel@mc.utmck.edu.

$\dagger$ Hrncic, R., Wall, J., Schell, M., Macy, S. D., Wolfenbarger, D., Weiss, D. T. & Solomon, A. (1999) *Blood* 94, Suppl. 1, 310 (abstr. 4614).

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. 5173a solely to indicate this fact.

of sonicated A $\beta$  fibrils. The sample was incubated 5–7 days until fibril growth was judged complete by a ThT assay (21).

The polyGln peptide was dissolved and disaggregated as described previously (22) by using a 1:1 mixture of trifluoroacetic acid and 1,1,1,3,3,3-hexafluoro-2-isopropyl alcohol, and then aggregated by incubation of a 0.05 mg/ml solution in PBSA at 37°C for 2 wk until reaction was judged complete by the ThT assay (21). PolyGln aggregates prepared in this manner exhibit strong  $\beta$ -sheet spectra and a typical amyloid ThT response but exhibit ribbon morphology rather than a classical amyloid morphology; based on these and other criteria, we refer to the aggregates as “amyloid-like” (S. Chen, V. Berthelie, J. B. Hamilton, B.O.N., and R.W., unpublished data).

Human IAPP was solubilized and disaggregated by using 1:1 trifluoroacetic acid/1,1,1,3,3,3-hexafluoro-2-isopropyl alcohol (22). After removal of volatile solvents, the peptide was dissolved in 2 mM NaOH and centrifuged at 20,800  $\times g$  for 25 min. The supernatant was diluted 1:2 by using a 2  $\times$  PBS stock containing 0.1% sodium azide, pH 7.4, to a final concentration of  $\approx$ 0.25 mg/ml. This solution was used immediately both to make amyloid fibrils and to fix monomers to microtiter plates. Fibrils were grown according to the protocol described above for A $\beta$ .

Fibrils were grown from  $\beta_2m$  and TTR in high salt and low pH as described (23, 24). Lysozyme fibrils were grown by a brief exposure to 65°C followed by incubation at 37°C in high salt at low pH (25).

All of the fibrils made as described above exhibited good amyloid fibril morphology by electron microscopy, with the exceptions that the IAPP aggregates appeared to be a mixture of classical amyloid fibrils and other organized structures (data not shown), and the polyGln aggregates appear to be protofilaments assembled into ribbons (26). All amyloid and amyloid-like aggregates exhibited typical ThT fluorescence (21, 27).

**Preparation of Aggregated Carboxymethylated Proteins.** Reduction and alkylation of the disulfides of ovalbumin and human serum albumin (HSA) was accomplished by dissolving the native protein to a concentration of 0.5 mg/ml in an argon-purged buffer consisting of 0.1 M Tris-HCl, 6 M guanidine hydrochloride, 2 mM DTT, and 1 mM EDTA, pH 8.5. Reactions were incubated at 37°C for 1.5 h with occasional gentle mixing. Iodoacetic acid was then added to a final concentration of 15 mM, and the reaction was incubated in the dark at room temperature for 1 hr then dialyzed overnight at 4°C against PBSA. Complete cleavage of disulfide bonds was confirmed by mobility shifts in nonreducing SDS/PAGE (28). Complete modification of thiol groups was demonstrated by using 5,5'-dithiobis(2-nitrobenzoic acid) (29). The PBSA solution of reduced and alkylated proteins was subjected to several rounds of freezing and thawing, after which the amount of material collected in a pellet after centrifugation was 50% or more of the entire protein sample. These suspensions (without centrifugation) were used to immobilize modified proteins onto microtiter plates.

**Hybridoma Isolation and mAb Purification.** A $\beta$ (1–40) fibrils were sonicated as described previously (20). Five standard, female BALB/c mice were immunized with 50  $\mu$ g/mouse/injection with sonicated fibrils. Two additional injections were given at 2-wk intervals. Bleeds were taken 1 wk after each injection and screened by using a modification of the microplate assay described below. After the third injection, two mice were killed and their spleens used to generate hybridoma cells. Initial screening of clones was performed by testing the ability of membranes containing uniformly deposited monomeric or fibrillar A $\beta$  to bind Abs from an array of clonal supernatants; the bound Abs were detected with secondary Abs against murine Ig. The hybridoma experiments, including the membrane blot survey of

initial hybridoma colonies, were conducted according to standard methods (30). Animal work, hybridoma creation, cloning, and preliminary screening were performed by the Hybridoma Development Facility at St. Louis University Health Center, St. Louis.

Clonal supernatants giving good binding to immobilized fibrils even in the presence of 80-fold weight excess monomeric A $\beta$  were considered to be good candidates for conformation-specific Abs and were carried forward in the cloning process. mAbs were produced from stable hybridoma cell lines by growing the cells in high density culture by using CELLline incubator flasks (INTEGRA Biosciences). mAbs were purified from the accumulated Ab-containing supernatants by using a HiTrap IgM purification affinity column (Amersham Pharmacia) followed by a Sephacryl S-300 (Amersham Pharmacia) size exclusion chromatography column (PBSA, 4°C). Nonreducing SDS/PAGE analysis confirmed the IgM isotype of the Abs and showed that they were at least 90% pure.


**Microtiterplate Assays of Fibril Binding.** Mouse sera and hybridoma supernatants were assayed for anti-fibril Abs as follows. First, 100 ng of sonicated A $\beta$ (1–40) fibrils in 100  $\mu$ l of PBSA was added to each well of a high-binding microtiter plate (Costar) and allowed to dry by incubating uncovered overnight in a 37°C oven. Plates were washed three times with PBSA containing 0.05% Tween 20 (the standard wash procedure for all subsequent steps of the protocol). Wells were blocked with 1% gelatin in PBSA at 37°C for 1 hr. Plates were then incubated with sera or hybridoma supernatants, with or without an 80-fold weight excess of monomeric A $\beta$ (1–40) with respect to immobilized fibrils, for 1 hr at 37°C and then washed three times. The signal was developed by incubation with a biotinylated Ab, followed by treatment with a streptavidin conjugate.

For measuring the IgG response in mouse sera (Fig. 1A), the secondary Ab was a mixture of isotype-specific goat anti-mouse IgG Abs (Sigma ISO-2 kit) diluted into 1% gelatin, 0.05% Tween 20, and PBSA. The tertiary Ab was a biotinylated rabbit anti-goat Ig Ab (Vector Laboratories). After incubation with a streptavidin-horseradish peroxidase conjugate (Vector Laboratories), the signal was developed with 3,3',5,5'-tetramethylbenzidine (TMB, Pierce no. 34021).

For measuring the IgG + IgM response in mouse sera (Fig. 1B), the secondary Ab was a biotinylated goat anti-mouse Ig Ab (Sigma), and the signal was developed with streptavidin-horseradish peroxidase as described above. For measuring the IgG + IgM response of hybridoma culture supernatants (Fig. 4), the same secondary Ab was used, but the signal was developed by using a europium-streptavidin conjugate (EG & G Wallac) and counted by using time-resolved fluorescence (31) on a Wallac Victor (2) fluorescence microtiter plate reader.

**Characterization of Binding Properties of Purified mAbs.** For experiments featuring immobilized ligands, microtiter plate wells were coated either with amyloid fibrils or other aggregates (as described above), or with soluble precursor proteins. For the latter, proteins in 2 mM sodium phosphate buffer, pH 7.4, containing 0.05% sodium azide, were incubated uncovered overnight in a 37°C oven. The low salt minimizes aggregation during the coating process (data not shown). After washing, plates were blocked with 3% BSA in PBSA for 1 h at 37°C. For the assay, Ab solutions were incubated 2 h at 37°C in the wells with 3% BSA in PBSA containing 0.05% Tween 20. Binding was quantified by using a biotinylated secondary Ab as described above. In the case of A $\beta$  fibrils, the ability of an 80-fold weight excess of monomeric peptide to inhibit Ab binding to fibrils was also assessed.

Binding of aggregates and soluble proteins to plastic by the above protocol was essentially quantitative. This was determined as follows. After overnight incubation as described, 50–150  $\mu$ l of




**Fig. 1.** Serum responses of mice immunized with Aβ(1-40) fibrils. Open bars show total Ig binding to 100 ng/well of amyloid fibrils immobilized onto microtiter plate wells. Closed bars show Ab binding to fibrils in the presence of a large excess of Aβ(1-40) monomer. (A) Increase in anti-amyloid IgG response over the course of the immunization treatment. (B) Total anti-amyloid IgG + IgM response of five immunized mice and a control at the completion of the immunization protocol.

PBS was added to several wells and incubated 10 min at room temperature. Supernatants from several wells were pooled and assayed for the amount of recovered protein, either by a micro protein assay (Pierce MicroBCA) or by recovery of aggregates, solubilization, and quantitation by HPLC against a standard curve (8). Less than 5% of the applied protein was recovered by such analyses, consistent with greater than 95% fixation of aggregates to the plastic.

For experiments featuring immobilized Abs, 100 μl of 15 nM mAb solutions in PBSA were sealed and incubated for 1.5 h at 37°C. Plates were washed and blocked with a 3% BSA solution in PBSA by incubation at 37°C for 1 hr. Various concentrations of biotinyl-Aβ(1-40) were added to each well, and the plate was incubated for 4 h at 37°C and then quantified as before by using streptavidin-europium and time-resolved fluorescence. The N-terminally biotinylated Aβ molecule was prepared by alkylating a Cys<sup>-1</sup> analog of Aβ(1-40) with PEO-iodoacetyl biotin (Pierce).

## Results and Discussion

Conformation-specific Abs against the native states of many proteins have been described. Such Abs bind well to the native, folded state of the protein, and less well, or not at all, to the denatured protein or to isolated peptide fragments (32). To isolate Abs specific for conformational epitopes of the Aβ fibril, mice were injected with sonicated Aβ fibrils. These mice mounted a time-dependent serum response consisting of Abs capable of binding to the amyloid form of Aβ immobilized on microtiter plate wells (Fig. 1). Significantly, a major portion of the anti-fibril Ab population binds to Aβ fibrils despite the presence of a large excess of monomeric Aβ (Fig. 1). This suggests that a major portion of the Abs are directed against



**Fig. 2.** Binding of purified mAbs to Aβ fibrils in the presence and absence of excess monomeric Aβ. Aβ(1-40) fibrils were immobilized on microplate wells and the wells incubated with anti-Aβ Abs in the absence (●) or presence of monomeric Aβ wild-type (Δ) or F19P mutant (□). (A) Binding of WO1. (B) Binding of the IgG mAb MAB1560 against a linear epitope (positions 1-17) of the Aβ(1-40) molecule.

conformational epitopes that only exist in the fibril. All five mice injected with amyloid exhibit similar serum responses (Fig. 1B). Hybridoma fusions were generated from the spleens of responsive mice and resulting cells screened and cloned by using a variety of assays (*Materials and Methods*) to isolate stable cell lines producing Abs that bind to Aβ fibrils but not to Aβ monomers.

Based on results from screening hybridoma supernatants, two stable cell lines, designated WO1 and WO2, were selected for further study. Reducing and nonreducing SDS/PAGE (not shown) of cell supernatants showed that both WO1 and WO2 have molecular weights in the 900-kDa range, consistent with the isotyping results on these supernatants showing that both Abs are of the IgM class. Light chains were isolated from the gels and subjected to amino acid sequence analysis. The light chain of WO1 exhibited the N-terminal sequence DIQMTQS, consistent with its being in the κ class of mouse light chains. WO2 appears to consist of a different light chain sequence because it exhibits a blocked N terminus, most consistent with a pyro-Glu residue derived from cyclization of a Gln side chain at position 1.

Fig. 2 compares the fibril-binding characteristics of WO1 to an anti-Aβ IgG mAb that recognizes a primary sequence epitope resident in the 1-17 sequence of Aβ. Fig. 2A shows that WO1 exhibits a saturable binding curve against immobilized Aβ fibrils with an EC<sub>50</sub>, or concentration of half-maximal binding, in the low nanomole range. Fig. 2A also shows that when a large weight excess of monomeric Aβ(1-40) is included in the incubation, strong binding to fibrils by WO1 is retained. (The apparent enhancement of binding of WO1 to amyloid fibrils in the presence of wild-type Aβ is probably due to higher fibril mass resulting from the extension of Aβ fibrils by the monomeric Aβ competitor during the incubation.) A soluble, proline-containing mutant incapable of making amyloid fibrils (33, 34), F19P-Aβ(1-40), also does not compete for WO1 binding to fibrils. In




Fig. 3. Binding of monomeric, soluble biotinyl-A $\beta$  to purified Abs immobilized on microplate wells. WO1 ( $\Delta$ ); WO2 ( $\blacktriangle$ ); control IgM ( $\square$ ); and anti-A $\beta$ (1-17) IgG MAB1560 ( $\circ$ ).

contrast, both mutant and wild-type monomeric A $\beta$  molecules effectively compete for binding to fibrils by an Ab directed against a linear epitope of A $\beta$ . Fig. 2B shows that an Ab directed at the linear 1-17 sequence of A $\beta$ , MAB1560, binds well to immobilized A $\beta$  fibrils. Fig. 2B shows that, in contrast to WO1 binding, MAB1560 binding to fibrils can be almost entirely eliminated when a large weight excess of monomeric, soluble A $\beta$  is included in the binding incubation. In these experiments, WO1 and MAB1560 exhibit significantly different binding amplitudes to the same weight of A $\beta$  fibrils; however, given the fact that different secondary Abs were used in these two panels, it is difficult to interpret this effect.

The experiments summarized in Fig. 2 provide indirect evidence that WO1 does not recognize monomeric A $\beta$ . More direct evidence is the demonstration that neither WO1 (Fig. 4) or WO2 (not shown) bind appreciably to monomeric A $\beta$ (1-40) immobilized onto microtiter plate wells. In addition, we find that monomeric A $\beta$ (1-40) is not able to bind to immobilized WO1 and WO2. Thus, Fig. 3 shows that although immobilized MAB1560 effectively binds N-terminally biotinylated A $\beta$ (1-40), immobilized WO1 and WO2, as well as a control IgM mAb, are completely ineffective at binding this peptide.

Surprisingly, WO1 and WO2 are capable of binding not only to A $\beta$  fibrils, but also to amyloid fibrils generated from other proteins. We generated amyloid fibrils from a number of amyloid precursor proteins (*Materials and Methods*). In each case the protein aggregates exhibit fibril or fibril-like structures in electron microscopy and a typical ThT fluorescence response (data not shown). Fig. 4A shows the binding of WO1 to equal weights of each of these amyloid fibrils immobilized onto microtiter plate wells. The figure shows that amyloid fibrils or amyloid-like aggregates composed of  $\beta_2$ m, IAPP, TTR, polyGln (Q<sub>42</sub>), the Ig V<sub>L</sub> domain JTO5 (35), and lysozyme [in addition to A $\beta$ (1-40)] are all capable of binding significant amounts of WO1. On a weight basis, WO1 binds different fibrils to different extents, exhibiting maximal binding to A $\beta$ (1-40) fibrils. The binding differences observed may be due in part to differences in binding constants (see below) and/or to different numbers of epitopes per unit weight of these amyloid fibrils. WO2 exhibited similar pan-amyloid binding (not shown).

In contrast to its broad ability to bind to amyloid fibrils, WO1 exhibits little or no binding to the precursor proteins for each of these fibrils immobilized onto microtiter plate wells (Fig. 4A). This result suggests that the conformation recognized by WO1 is absent in the native precursor proteins. Fig. 4A also shows that




Fig. 4. Binding of WO1 to various aggregates. Open bars, binding to immobilized aggregate; gray bars, binding to immobilized monomeric form; and filled bar, binding to immobilized aggregate in the presence of an 80-fold weight excess monomeric F19P-A $\beta$ (1-40). (A) Binding to various amyloids and their precursor proteins. (B) Binding to nonamyloid biological aggregates and nonnative globular protein aggregates. In these experiments, WO1 was used as a hybridoma supernatant diluted 1:2 in PBSA.

WO1 binds to A $\beta$  fibrils despite the presence of a high weight excess of soluble A $\beta$ .

To probe the specificity of WO1 and WO2 for amyloid fibrils, we tested WO1 binding to different kinds of protein aggregates. Fig. 4B shows that WO1 does not bind appreciably to the fibrous proteins collagen and elastin, or to gelatin, the denatured form of collagen. Many globular proteins aggregate in response to disruption of their native states by chemical or physical stress, and these aggregates are often dominated by  $\beta$ -sheet structure (36). Fig. 4B shows, however, that WO1 does not bind to aggregates of ovalbumin or human serum albumin induced by denaturation via reduction and alkylation. Similar results were obtained for WO2 (not shown). These results show that the epitope(s) recognized by WO1 and WO2 is not a structural feature shared with amorphous protein aggregates, such as interchain  $\beta$ -sheet or diffuse patches of surface-exposed hydrophobicity. Thus, results to date suggest that the epitope recognized by these Abs is specific to the amyloid state of proteins.

To quantitatively assess the crossreactivity of WO1 and WO2 against other amyloid fibrils, we determined full binding curves for these Abs, as well as for a control  $\kappa$  light chain IgM, against amyloid fibrils composed of A $\beta$ (1-40), JTO5, and IAPP. Fig. 5A shows that WO1 and WO2 exhibit saturable binding curves to immobilized A $\beta$ (1-40) fibrils (the original immunogen) with EC<sub>50</sub>s of 2.8 nM and 1.3 nM, respectively. In contrast, the binding of a  $\kappa$  light chain control IgM to A $\beta$ (1-40) fibrils exhibited a much weaker binding constant (121 nM) and a lower binding amplitude. The binding ability of this control IgM to A $\beta$  fibrils




Fig. 5. Binding curves for purified WO1, WO2, and a control  $\kappa$  chain IgM against various amyloid fibrils immobilized onto microplate wells. WO1 ( $\circ$ ); WO2 ( $\blacksquare$ ); and IgM control ( $\triangle$ ). (A)  $A\beta(1-40)$  fibrils. (B) Ig light chain variable domain JTO5 fibrils. (C) IAPP fibrils. Data in B and C are from single replicate determinations.

is probably related to the general ability of globular proteins to bind nonspecifically to  $A\beta$  fibrils (B.O.N. and R.W., unpublished observations). Interestingly, a  $\lambda$  chain control IgM is much less effective at binding to  $A\beta$  fibrils compared to the control  $\kappa$  chain IgM (data not shown).

Fig. 5B shows that WO1 and WO2 bind to JTO5 fibrils with  $EC_{50}$  values of 2.8 nM and 1.2 nM, respectively, values similar to those for binding to  $A\beta(1-40)$  fibrils. The amplitudes for WO1 and WO2 binding to JTO5 fibrils, although differing from each other by about a factor of three, are in the same range as the binding of these Abs to  $A\beta$  fibrils. The control  $\kappa$  light chain IgM exhibits essentially no binding to JTO5 fibrils. Fig. 5C shows that WO1 and WO2 also bind with similar amplitudes and binding constants (1.7 nM and 1.0 nM, respectively) to IAPP fibrils, whereas the control IgM binds negligibly. These data dramatically illustrate that WO1 and WO2 recognize what appears to be a universal amyloid epitope and that the ability to bind to amyloid fibrils is not shared by a control IgM. The Abs bind with similar strengths to amyloids other than the  $A\beta(1-40)$  amyloid

immunogen. Although the IAPP peptide exhibits some amino acid sequence homology to  $A\beta(1-40)$  (P. Westermark, personal communication), JTO5 offers no significant homology. [This was confirmed by using the SIM (37), LALIGN (38), and DOTLET (39) sequence alignment programs ([www.expasy.ch/tools](http://www.expasy.ch/tools)) (data not shown)]. The nature of the common amyloid epitope, therefore, does not seem to depend on extensive amino acid side chain information. This point is made perhaps most dramatically by the fact that WO1 binds well to polyGln aggregates (Fig. 4A), which exhibit a number of amyloid-like features in their morphologies and biophysical properties (S. Chen, V. Berthelie, J. B. Hamilton, B.O.N., and R.W., unpublished data).

In their abilities to bind to multiple molecular species, WO1 and WO2 bear some resemblance to polyreactive Abs such as the anti-DNA Abs produced in certain autoimmune conditions. Although little is known about the basis for such polyreactive binding recognition, at least some anti-DNA Abs are thought to recognize repeat structures within DNA such as heteroaromatic bases or phosphate groups (40, 41). As highly ordered polymers, amyloid fibrils presumably also exhibit certain kinds of regular structural repeats that might serve as the basis for multidentate-binding recognition. The extent to which WO1 and WO2 binding to amyloid might depend on such multidentate binding is yet to be determined.

One possible contributor to a common amyloid structural epitope might be a unique array of H-bond donor and acceptor groups from the polypeptide backbone at the edge strands of the  $\beta$ -sheets on the ends of amyloid fibrils. If so, this configuration must be different from that of the edge strands of  $\beta$ -sheets in the native states of  $\beta$ -sandwich-based proteins such as the Fv domain and TTR because these globular, native proteins do not bind WO1 and WO2 appreciably (Fig. 4). Another possibility is main chain elements involved in some unusual turn or chain reversal within the amyloid motif. Detailed structures of the epitopes of anti-protein Abs are normally characterized either by protein crystallography (42) or by mutational analysis of antigen fragments (43) or intact protein (44). Because amyloid has yet to be crystallized, and because WO1 and WO2 bind to many amyloids regardless of amino acid sequence, it is clear that the further structural analysis of the WO1/WO2 epitope(s) will be challenging.

$A\beta(1-40)$  fibrils are not unique in their ability to stimulate production of generic anti-amyloid Abs in mice. For example, a mAb raised against an amyloidogenic Ig light chain fragment has been reported to recognize tissue amyloid deposits composed of the light chain variable domain,  $A\beta$ , and other amyloidogenic proteins (13). The reciprocity of these results with those described here further supports the existence of an epitope that is a universal signature of the amyloid fibril.

Abs such as WO1 and WO2 are important for a number of reasons. They may prove invaluable in improving our knowledge of the three-dimensional structures of amyloid fibrils. Such Abs will also allow us to monitor more closely the generation of the amyloid epitope during assembly *in vitro* and *in vivo*. Fibril-specific Abs may be useful as passive vaccines in anti-amyloid therapy (13, 15, 16,  $\dagger$ ). Furthermore, recognition that an amyloid fibril from one precursor protein can stimulate a pan-amyloid response in an animal suggests that amyloid fibrils composed of one constituent protein might serve as vaccines against other types of amyloid. Finally, Abs such as WO1 and WO2 may prove to be useful diagnostic reagents not only for Alzheimer's disease, but also for other protein aggregation diseases. The defining clinical test for the presence of amyloid in tissue continues to be birefringence after Congo red staining (12). However, as a technique that is inherently limited in resolution to the wavelength of visible light, Congo red birefringence is not capable of detecting deposits of small and/or disorganized fibrils if they do not exhibit macroscopic order. Abs such as WO1 and WO2

may thus prove to be more reliable probes for the presence of the amyloid-folding motif in tissue samples.

We gratefully acknowledge Charles Murphy for the amino acid sequence analysis of IgM light chains, Yesim Aydin Son for preliminary binding

studies, and Dennis Wolfenbarger for help with preliminary immunization studies. We also thank Per Westermark for the gift of human IAPP, Jonathan Wall for the gift of soluble and fibrillar recombinant JTOS, Jonathan Wall and Alan Solomon for helpful discussions, and Fred Stevens for pointing out the limitations of Congo red birefringence.

- Falk, R. H., Comenzo, R. L. & Skinner, M. (1997) *N. Engl. J. Med.* **337**, 898–909.
- Martin, J. B. (1999) *N. Engl. J. Med.* **340**, 1970–1980.
- Selkoe, D. J. (1997) *Science* **275**, 630–631.
- Kahn, S. E., Andrikopoulos, S. & Verchere, C. B. (1999) *Diabetes* **48**, 241–253.
- Sipe, J. D. (1992) *Annu. Rev. Biochem.* **61**, 947–975.
- Wetzel, R. (1999) in *Methods in Enzymology*, eds. Abelson, J. N. & Simon, M. I. (Academic, San Diego), pp. 820.
- Town, T., Tan, J., Sansone, N., Obregon, D., Klein, T. & Mullan, M. (2001) *Neurosci. Lett.* **307**, 101–104.
- Kheterpal, I., Williams, A., Murphy, C., Bledsoe, B. & Wetzel, R. (2001) *Biochemistry* **40**, 11757–11767.
- Linke, R. P., Zucker-Franklin, D. & Franklin, E. C. (1973) *J. Immunol.* **111**, 10–23.
- Goldsteins, G., Persson, H., Andersson, K., Olofsson, A., Dacklin, I., Edvinsson, A., Saraiva, M. J. & Lundgren, E. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 3108–3113.
- Korth, C., Stierli, B., Streit, P., Moser, M., Schaller, O., Fischer, R., Schulz-Schaeffer, W., Kretzschmar, H., Raebler, A., Braun, U., et al. (1997) *Nature (London)* **390**, 74–77.
- Westermark, G. T., Johnson, K. H. & Westermark, P. (1999) *Methods Enzymol.* **309**, 3–25.
- Hrncic, R., Wall, J., Wolfenbarger, D. A., Murphy, C. L., Schell, M., Weiss, D. T. & Solomon, A. (2000) *Am. J. Pathol.* **157**, 1239–1246.
- Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) *Nature (London)* **400**, 173–177.
- Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) *Nat. Med.* **6**, 916–919.
- Peretz, D., Williamson, R. A., Kaneko, K., Vergara, J., Leclerc, E., Schmitt-Ulms, G., Mehlhorn, I. R., Legname, G., Wormald, M. R., Rudd, P. M., et al. (2001) *Nature (London)* **412**, 739–743.
- Solomon, B., Koppel, R., Frankel, D. & Hanan-Aharon, E. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 4109–4112.
- Solomon, B., Koppel, R., Hanan, E. & Katzav, T. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 452–455.
- O’Nuallain, B. & Wetzel, R. (2001) *Protein Sci.* **10**, 87–88.
- Kheterpal, I., Zhou, S., Cook, K. D. & Wetzel, R. (2000) *Proc. Natl. Acad. Sci. USA* **97**, 13597–13601.
- LeVine, H. (1999) *Methods Enzymol.* **309**, 274–284.
- Chen, S. & Wetzel, R. (2001) *Protein Sci.* **10**, 887–891.
- Colon, W. & Kelly, J. W. (1992) *Biochem.* **31**, 8654–8660.
- McParland, V. J., Kad, N. M., Kalverda, A. P., Brown, A., Kirwin-Jones, P., Hunter, M. G., Sunde, M. & Radford, S. E. (2000) *Biochemistry* **39**, 8735–8746.
- Krebs, M. R., Wilkins, D. K., Chung, E. W., Pitkeathly, M. C., Chamberlain, A. K., Zurdo, J., Robinson, C. V. & Dobson, C. M. (2000) *J. Mol. Biol.* **300**, 541–549.
- Chen, S., Berthelcier, V., Yang, W. & Wetzel, R. (2001) *J. Mol. Biol.* **311**, 173–182.
- Naiki, H., Higuchi, K., Hosokawa, M. & Takeda, T. (1989) *Anal. Biochem.* **177**, 244–249.
- Plunkett, G. & Ryan, C. A. (1980) *J. Biol. Chem.* **255**, 2752–2755.
- Zahler, W. L. & Cleland, W. W. (1968) *J. Biol. Chem.* **243**, 716–719.
- Harlow, E. & Lane, D. (1988) *Antibodies: A Laboratory Manual* (Cold Spring Harbor Lab. Press, Plainview, NY).
- Diamandis, E. P. (1988) *Clin. Biochem.* **21**, 139–150.
- Laver, W. G., Air, G. M., Webster, R. G. & Smith-Gill, S. J. (1990) *Cell* **61**, 553–556.
- Wood, S. J., Wetzel, R., Martin, J. D. & Hurle, M. R. (1995) *Biochemistry* **34**, 724–730.
- Teplow, D. B., Lomakin, A., Benedek, G. B., Kirschner, D. A. & Walsh, D. M. (1997) in *Alzheimer’s Disease: Biology, Diagnosis and Therapeutics*, eds. Iqbal, K., Winblad, B., Nishimura, T., Takeda, M. & Wisniewski, H. M. (Wiley, New York), pp. 313–321.
- Wall, J., Schell, M., Murphy, C., Hrncic, R., Stevens, F. J. & Solomon, A. (1999) *Biochemistry* **38**, 14101–14108.
- Fink, A. L. (1998) *Folding Des.* **3**, R9–R23.
- Huang, X. & Miller, W. (1991) *Adv. Appl. Math.* **12**, 337–357.
- Duret, L., Gasteiger, E. & Perriere, G. (1996) *Comput. Appl. Biosci.* **12**, 507–510.
- Junier, T. & Pagni, M. (2000) *Bioinformatics* **16**, 178–179.
- Fermand, J. P., Danon, F. & Brouet, J. C. (1985) *Clin. Exp. Immunol.* **59**, 467–474.
- Eilat, D. & Anderson, W. F. (1994) *Mol. Immunol.* **31**, 1377–1390.
- Padlan, E. A., Silverton, E. W., Sheriff, S., Cohen, G. H., Smith-Gill, S. J. & Davies, D. R. (1989) *Proc. Natl. Acad. Sci. USA* **86**, 5938–5942.
- Getzoff, E. D., Geysen, H. M., Rodda, S. J., Alexander, H., Tainer, J. A. & Lerner, R. A. (1987) *Science* **235**, 1191–1196.
- Li, Y., Lipschultz, C. A., Mohan, S. & Smith-Gill, S. J. (2001) *Biochemistry* **40**, 2011–2022.